


CLAIMS:

1. A compound of formula I:

5

10

15



20

or a pharmaceutically acceptable salt thereof,
wherein:

X is selected from a valence bond, $-\text{CH}_2-$, $-\text{NH}-$, $-\text{S}-$ or $-\text{O}-$;

Z is selected from $=\text{CH}-$ or $=\text{N}-$;

Y is selected from a valence bond or $-\text{CH}_2-$;

25

R2 is hydrogen or methyl and R1 is selected from

30

R1 is hydrogen or methyl and R2 is selected from $-\text{H}$, $\text{Q}-\text{CO}_2\text{H}$, $\text{Q}-1H\text{-tetrazol-5-yl}$, $\text{Q}-\text{CN}$, or $\text{Q}-\text{R}_5$, wherein R5 is a functional group that is hydrolyzed to $-\text{CO}_2\text{H}$ in physiological conditions, wherein each Q is independently selected from a valence bond or an optionally substituted C1-3 alkylidene chain, wherein one or two

non-adjacent methylene units of Q are optionally and independently replaced by -O-, -S- or -NH-;

Ar1 and Ar2 are independently selected from a 3-10
5 membered monocyclic or bicyclic saturated or unsaturated cycloalkyl, an ensemble of two 3-8 membered monocyclic rings covalently linked by a C-, N-, O- or S-atom, or 5-10 membered monocyclic or bicyclic aryl ring having 0-4 heteroatoms independently selected
10 from nitrogen, oxygen, or sulphur, wherein Ar1 and/or Ar2 is optionally and independently substituted by one to four R3 groups and each R3 is independently selected from -R5-trifluoromethyl, -R6-R4, -R6-F, -R6-Cl, -R6-Br, -R6-J, -R6-NO₂, -R6-CN, -R6-O-R4,
15 -R6-(CH₂)_n-O-R4 (n=1,2,3,4,5,6,7, or 8), -R6-S-R4, -R6-N(R4)₂, -R6-NR4-CO-R4, -R6-NR4-CO-N(R4)₂, -R6-NR4-CO-O-R4, -R6-CO-R4, -R6-CO-O-R4, -R6-CO-N(R4)₂, -R6-O-CO-N(R4)₂, -R6-SO-R4, -R6-SO₂R4, -R6-SO₂N(R4)₂, -R6-NR4-SO₂R4, -R6-NR4-SO₂N(R4)₂,
20 -R6-CO-NR4-CO-R4, or -R6-CO-CH₂-CO-R4; wherein each R4 is independently selected from hydrogen, or from an optionally substituted C1-6 aliphatic group, wherein R6 is a valence bond or a bivalent spacer group, in particular C1-6 aliphatic group, and wherein two R3
25 on adjacent positions on Ar3 are optionally taken together to form a saturated, partially unsaturated, or fully unsaturated 4-6 membered ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulphur.

30

2. A compound according to claim 1, wherein Ar1 and Ar2 are independently 3-8 membered monocyclic, or 8-10

membered bicyclic cycloalkyl, or 5-6 membered monocyclic or 8-10 bicyclic aryl ring, or 5-6 membered monocyclic or 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms.

5

3. A compound according to claim 1 or 2, wherein Ar1 and Ar2 are independently selected from phenyl, indolyl, naphthyl, pyrimidinyl, pyridinyl, quinolyl, or isoquinolyl, wherein as an option Ar1 and/or Ar2 is substituted by 1-4 R3 groups.
- 10
4. A compound according to one of the claims 1 to 3, wherein X is a valence bond, Z is a nitrogen, Y is -CH₂-, R2 is -H, and R1 is selected from -Q-CO₂H, Q-1H-tetrazol-5-yl, -Q-CN, wherein each Q is independently selected from a valence bond or an optionally substituted C1-3 alkylidene chain, wherein one or two non-adjacent methylene units of Q are optionally and independently replaced by -O-, -S- or -NH-.
- 15
- 20
5. A compound according to one of the claims 1 to 3, wherein X is a valence bond, Z is =CH-, Y is a valence bond, R2 is -H, and R1 is selected from -Q-CO₂H, Q-1H-tetrazol-5-yl, -Q-CN, wherein each Q is independently selected from a valence bond or an optionally substituted C1-3 alkylidene chain, wherein one or two non-adjacent methylene units of Q are optionally and independently replaced by -O-, -S- or -NH-.
- 25
- 30

6. A compound according to one of the claims 1 to 3,
wherein X is -NH-, Z is =CH-, Y is a valence bond, R2
is -H, and R1 is selected from -Q-CO₂H,
Q-1H-tetrazol-5-yl, -Q-CN, wherein each Q is inde-
pendently selected from a valence bond or an option-
ally substituted C1-3 alkylidene chain, wherein one
or two non-adjacent methylene units of Q are option-
ally and independently replaced by -O-, -S- or -NH-.
7. A compound according to one of the claims 1 to 3,
wherein X is -NH-, Z is =CH-, Y is a valence bond, R1
is -H, and R2 is selected from -Q-CO₂H,
Q-1H-tetrazol-5-yl, -Q-CN, wherein each Q is inde-
pendently selected from a valence bond or an option-
ally substituted C1-3 alkylidene chain, wherein one
or two non-adjacent methylene units of Q are option-
ally and independently replaced by -O-, -S- or -NH-.
8. A compound according to one of the claims 1 to 7 be-
ing effective to modulate and/or regulate in vitro
and/or in vivo the activity of an AGC kinase contain-
ing a PIF pocket homologous site in the small lobe of
the kinase domain, in particular being effective to
activate or inhibit PDK1 and/or PKB.
9. Use of a compound according to one of the claims 1 to
8 for the preparation of a pharmaceutical
composition.

10. Use according to claim 9, wherein a physiologically effective dose of the compound is mixed with a pharmaceutically acceptable carrier.
- 5
11. Use according to one of the claims 9 or 10, for the preparation of a pharmaceutical composition for the prevention or treatment of a disease related to an AGC kinase, in particular PDK1 and/or PKB, having an abnormal high or low activity.
- 10
12. Method for preventing or treating a disease related to an AGC kinase, in particular PDK1 and/or PKB, having an abnormal high or low activity, wherein a compound according to one of the claims 1 to 8 or a pharmaceutical composition according to one of the claims 9 to 11 is administered to an organism having the risk of obtaining the disease or suffering from the disease in a physiologically effective dose.
- 15
- 20

25

30